Serrapeptase labels are unusually hard to compare, because the most prominent number on them can be constructed several different ways. These eight questions are the ones that change the answer. They are written to be asked of any product, including this one.
Compare on the activity basis, not the headline figure. Then ask whether the number is declared or measured, whether the document behind it names your lot and an accredited laboratory, and whether the finished capsule — not just the ingredient — was tested. Everything else is secondary.
1. Is the SPU figure per capsule or per full daily dose?
Start here, because it silently rewrites every other comparison. A product stating a large figure across two or three capsules may deliver less activity per capsule than one stating a smaller figure for a single capsule. Find the serving size on both labels and normalize before comparing. Background: What Does SPU Mean in Serrapeptase?.
2. Is that figure a declared specification or a measured result?
A declared specification is what the product is formulated to. A measured result is what an assay found in a specific lot. Both are legitimate; they are not the same statement, and only one of them is evidence about a bottle. See Declared Potency vs. Measured Enzyme Activity.
3. Is there documentation for the specific lot you would receive?
A published test result is only as specific as the lot it names. Ask whether you can retrieve a document for the lot number printed on your own bottle, or only a single document representing the product line in general.
4. Who ran the test, and is the laboratory accredited?
Look for a named laboratory and its accreditation status — ISO 17025 is the relevant standard for testing-laboratory competence. A brand-produced summary of results is a different object from the laboratory document. The full framework for reading one is in How to Read a Serrapeptase Certificate of Analysis.
5. Is the delivery format described specifically enough to evaluate?
“Protected” and “advanced delivery” are not formats. A format is a description you could check: a delayed-release shell, an enteric coating, coated pellets, a specific stated mechanism. If a product does not describe its format specifically, there is nothing to evaluate.
6. Was the finished capsule tested, or only the ingredient?
Delivery claims can only be evaluated on the finished dosage form, because the capsule is the thing doing the work. A raw-material document cannot speak to how a capsule behaves. If disintegration testing is claimed, ask under which standard — and see what USP <2040> actually tests for what such a result does and does not establish.
7. What else is in the capsule?
Read the full ingredient statement, not the front panel. Fillers, flow agents, and coatings are all legitimate parts of manufacturing; the point is that they should be legible to you before purchase rather than after.
8. How much of this can you verify yourself, before buying?
This is the question that ranks all the others. Some claims can be checked by anyone with the label and a browser; some can be checked only after the bottle arrives; some cannot be checked at all. A product whose evidence you can inspect before purchase is making a different kind of offer than one whose evidence is described to you.
What this framework will not do
It will not tell you what a supplement will do for you. These eight questions are about the quality and specificity of the evidence a product offers — not about outcomes, which no label comparison can establish. Questions about whether a supplement is appropriate for you belong with a healthcare professional who knows your situation.
How iSerra approaches it
For the record, the same eight questions applied here: activity stated as 250,000 SPU per capsule; every lot assayed and its own measured result documented; documentation retrievable by the lot number on your bottle through Veriphase™; identity, potency, heavy-metals, and microbial results on an independent ISO 17025-accredited laboratory COA; delivery format described specifically as Bilamex™ Dual-Phase Delivery, a delayed-release shell plus individually coated pellets; and finished-capsule disintegration evaluated under USP <2040>.
That is a description of what is documented, not an argument that documentation settles every question. The point of the framework is that you can apply it yourself.
Practical takeaway
Normalize the activity figure. Establish whether it is declared or measured. Then ask what you can see for your own lot, from a named laboratory, about the finished capsule. Four steps, in that order, will separate most products in this category faster than any feature list.
The useful question is never which label sounds most confident. It is which claims you can check before you decide.
ISO/IEC 17025 laboratory competence standard; USP <2040> disintegration standard for delayed-release dosage forms; USP proteolytic assay conventions for enzyme activity. Reference detail maintained on The Science.
iSerra™ declared specification 250,000 SPU per capsule; per-lot 14-test panel; Bilamex™ Dual-Phase Delivery format description; Veriphase™ per-lot COA lookup.
Published research on an ingredient, finished-product testing, and lot-specific testing are three different categories of evidence and are kept separate throughout the Journal. This article introduces no external findings beyond those referenced on The Science.